JamesDavidMarksMD

Critical Care Medicine

Professor, Anesthesia & Perioperative Care, UCSF School of Medicine

Dr. Marks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1001 Potrero Ave
Rm 3c34
San Francisco, CA 94110
Phone+1 415-206-8934

Fax+1 415-206-3101

University of California (San Francisco)Residency, Anesthesiology, 1984 - 1986
University of California (San Francisco)Fellowship, Critical Care Medicine (Anesthesiology), 1982 - 1983
University of California (San Francisco)Residency, Internal Medicine, 1979 - 1982
University of California San Francisco School of MedicineClass of 1979

PubMed

219 citations
Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome.
D B Rubin, Jeanine P. Wiener-Kronish, John Murray, D R Green, Jerrold R. Turner
The Journal of Clinical Investigation. 1990-08-01
456 citations
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby
Clinical Cancer Research. 2002-04-01
38 citations
Development of Human Single-Chain Antibodies to the Transferrin Receptor that Effectively Antagonize the Growth of Leukemias and Lymphomas
Ronan Philippe Crepin, Anne-Laure Goenaga, Betsy Jullienne, Houcine Bougherara, Christine Legay
Cancer Research. 2010-07-01

Evolving Diagnostic Antibodies For Botulinum NeurotoxinsNational Institute Of Allergy And Infectious Diseases2011–2012
Development Of Botulinum Neurotoxin Immunotherapy, Serotypes C, D, F, And GNational Institute Of Allergy And Infectious Diseases2007–2011
Using Mass Spec To Determine Molecular Identity Of Tumor Specific AntigenNational Center For Research Resources2004–2011
Design And Generation Of Cross- Reactive Botulinum Neurotoxin AntibodiesNational Institute Of Allergy And Infectious Diseases2009–2010
Development Of Botulinum Neurotoxin ImmunotherapyNational Institute Of Allergy And Infectious Diseases2003–2007
Deciphering Toxin Neutralization By Oligoclonal AntibodyNational Institute Of Allergy And Infectious Diseases2002–2003
Phage Antibody Based Probes Of ERBB Receptor FunctionNational Cancer Institute2001–2002